Payment overview · 2025
General Payments
$1,130.47
92 reported records · 12 companies
Healthcare provider profile · identity verified
Chandos Dewayne Tackett, MD
Allopathic & Osteopathic Physicians|Family Medicine · HUNTINGTON, WV · NPI 1912933151
Verified facts
What the public records show
CMS Open Payments records show Chandos Dewayne Tackett, MD received $1,130.47 in general payments during 2025 across 92 reported records.
ABBVIE INC. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 431 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 431 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $262.70 | 23.2% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $240.34 | 21.3% | 28 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $208.38 | 18.4% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $137.18 | 12.1% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $134.62 | 11.9% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $48.01 | 4.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.83 | 3.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.39 | 1.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $14.12 | 1.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.80 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.54 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4.56 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,130.47 | 92 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $209.39 | 16 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $177.38 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $168.46 | 20 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $137.18 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $123.57 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $99.48 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.21 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $60.97 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $54.12 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.09 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.37 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.83 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $32.43 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $11.05 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $11.05 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $9.94 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 431 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 194 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 28 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 231 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
115 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
194 | 40 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
431 | 97 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
231 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
431 | 97 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 1107 | 308 |
| Levothyroxine Sodium | Levothyroxine Sodium | 988 | 249 |
| Metoprolol Succinate | Metoprolol Succinate | 958 | 271 |
| Lisinopril | Lisinopril | 948 | 240 |
| Atorvastatin Calcium | Atorvastatin Calcium | 868 | 251 |
| Amlodipine Besylate | Amlodipine Besylate | 815 | 226 |
| Gabapentin | Gabapentin | 801 | 165 |
| Alprazolam | Alprazolam | 622 | 90 |
| Losartan Potassium | Losartan Potassium | 600 | 179 |
| Furosemide | Furosemide | 524 | 170 |
| Trazodone Hcl | Trazodone Hcl | 520 | 149 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 484 | 137 |
| Metformin Hcl | Metformin Hcl | 468 | 139 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 466 | 72 |
| Eliquis | Apixaban | 431 | 97 |
| Simvastatin | Simvastatin | 414 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 412 | 121 |
| Sertraline Hcl | Sertraline Hcl | 392 | 88 |
| Pravastatin Sodium | Pravastatin Sodium | 391 | 107 |
| Duloxetine Hcl | Duloxetine Hcl | 365 | 103 |
| Tramadol Hcl | Tramadol Hcl | 359 | 67 |
| Potassium Chloride | Potassium Chloride | 353 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 337 | 127 |
| Ezetimibe | Ezetimibe | 323 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 315 | 90 |
| Famotidine | Famotidine | 290 | 78 |
| Clopidogrel | Clopidogrel Bisulfate | 286 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 285 | 107 |
| Carvedilol | Carvedilol | 284 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 260 | 82 |
| Glimepiride | Glimepiride | 249 | 69 |
| Prednisone | Prednisone | 245 | 141 |
| Metformin Hcl Er | Metformin Hcl | 243 | 74 |
| Montelukast Sodium | Montelukast Sodium | 238 | 71 |
| Allopurinol | Allopurinol | 234 | 67 |
| Ozempic | Semaglutide | 231 | 40 |
| Donepezil Hcl | Donepezil Hcl | 218 | 45 |
| Alendronate Sodium | Alendronate Sodium | 214 | 63 |
| Lorazepam | Lorazepam | 205 | 28 |
| Jardiance | Empagliflozin | 194 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 184 | 45 |
| Buspirone Hcl | Buspirone Hcl | 183 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 180 | 61 |
| Meloxicam | Meloxicam | 168 | 48 |
| Spironolactone | Spironolactone | 168 | 52 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 165 | 41 |
| Torsemide | Torsemide | 160 | 48 |
| Ibuprofen | Ibuprofen | 159 | 41 |
| Bupropion Xl | Bupropion Hcl | 156 | 57 |
| Citalopram Hbr | Citalopram Hydrobromide | 155 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 155 | 61 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 152 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 152 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 151 | 108 |
| Mirtazapine | Mirtazapine | 147 | 38 |
| Methocarbamol | Methocarbamol | 145 | 67 |
| Tizanidine Hcl | Tizanidine Hcl | 135 | 35 |
| Celecoxib | Celecoxib | 133 | 40 |
| Mounjaro | Tirzepatide | 132 | 23 |
| Nateglinide | Nateglinide | 120 | 29 |
| Pregabalin | Pregabalin | 119 | 24 |
| Synthroid | Levothyroxine Sodium | 115 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 112 | 29 |
| Primidone | Primidone | 112 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 30 |
| Nystatin | Nystatin | 111 | 53 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 108 | 28 |
| Atenolol | Atenolol | 106 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 104 | 66 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 103 | 26 |
| Methylprednisolone | Methylprednisolone | 102 | 85 |
| Valsartan | Valsartan | 100 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 96 | 25 |
| Finasteride | Finasteride | 95 | 27 |
| Xarelto | Rivaroxaban | 95 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 32 |
| Azithromycin | Azithromycin | 91 | 78 |
| Ipratropium Bromide | Ipratropium Bromide | 91 | 43 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 86 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 21 |
| Lovastatin | Lovastatin | 80 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 80 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 77 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 24 |
| Topiramate | Topiramate | 77 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 14 |
| Clonazepam | Clonazepam | 72 | 11 |
| Myrbetriq | Mirabegron | 71 | suppressed |
| Trulicity | Dulaglutide | 71 | 11 |
| Warfarin Sodium | Warfarin Sodium | 71 | 18 |
| Nifedipine Er | Nifedipine | 70 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 53 |
| Fenofibrate | Fenofibrate | 66 | 18 |
| Zaleplon | Zaleplon | 65 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 64 | 15 |
| Glipizide Er | Glipizide | 61 | 17 |
| Amoxicillin | Amoxicillin | 60 | 47 |
| Meclizine Hcl | Meclizine Hcl | 60 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 34 |
| Sulindac | Sulindac | 59 | 19 |
| Memantine Hcl | Memantine Hcl | 57 | 16 |
| Lactulose | Lactulose | 56 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 41 |
| Diazepam | Diazepam | 55 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 55 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | suppressed |
| Fluconazole | Fluconazole | 52 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 12 |
| Januvia | Sitagliptin Phosphate | 52 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 51 | 15 |
| Premarin | Estrogens, Conjugated | 51 | suppressed |
| Cefdinir | Cefdinir | 50 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 11 |
| Naproxen | Naproxen | 47 | 15 |
| Colestipol Hcl | Colestipol Hcl | 46 | 17 |
| Hydrocortisone | Hydrocortisone | 46 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 12 |
| Cephalexin | Cephalexin | 44 | 21 |
| Farxiga | Dapagliflozin Propanediol | 43 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 17 |
| Lansoprazole | Lansoprazole | 41 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 12 |
| Nitroglycerin | Nitroglycerin | 40 | 27 |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Ketoconazole | Ketoconazole | 39 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | 11 |
| Methotrexate | Methotrexate Sodium | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 26 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Felodipine Er | Felodipine | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Metronidazole | Metronidazole | 32 | 19 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 32 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 30 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Linzess | Linaclotide | 28 | 12 |
| Repatha Syringe | Evolocumab | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Febuxostat | Febuxostat | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 14 |
| Klor-Con M20 | Potassium Chloride | 25 | 11 |
| Lagevrio (Eua) | Molnupiravir | 25 | 24 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | 12 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | 11 |
| Digoxin | Digoxin | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Trimethoprim | Trimethoprim | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 11 |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Methadone Hcl | Methadone Hcl | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Desloratadine | Desloratadine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | 11 |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Lidocaine | Lidocaine | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,130.47 · 92 records | ABBVIE INC. | AREXVY, CAMZYOS, ELIQUIS, ENTRESTO, EVENITY, JARDIANCE, LEQVIO, LINZESS, NURTEC ODT, NUZYRA, Ozempic, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error